Welcome to our dedicated page for Invitae Corporation news (Ticker: $NVTA), a resource for investors and traders seeking the latest updates and insights on Invitae Corporation stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Invitae Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Invitae Corporation's position in the market.
Rhea-AI Summary
Invitae (NVTA) completes the sale of reproductive health assets to Natera (NTRA) for up to $52.5 million, aiming to focus on clinical germline genetic information and reduce operating expenses by approximately $44 million annually. Natera has hired Invitae reproductive health sales representatives and will take over customer transition for non-invasive prenatal and carrier screening.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
-
Rhea-AI Summary
Invitae (NVTA) divests Ciitizen assets, maintains minority equity stake, and anticipates $90-100 million annual cash savings. The company also implements strategic cost cuts and workforce reduction to streamline operations and reduce cash burn.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.36%
Tags
-
Rhea-AI Summary
Invitae Corporation: Aranscia acquires select assets of YouScript personalized medication management platform from Invitae Corporation, a leader in medical genetics. YouScript's PGx insights enable healthcare providers to scale personalized medication management programs. YouScript joins Aranscia's portfolio of companies, including 2bPrecise, SinguLab, and AccessDx Laboratory, to democratize precision medicine. Studies show PGx testing with YouScript's technology led to a 71% reduction in hospital emergency visits, 39% reduction in admissions, and $1,132 in estimated cost savings in just four months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
Rhea-AI Summary
NVTA: Invitae Reports $121.2M Q3 Revenue, 9% YoY Decrease; Pro Forma Revenue Up 4%; Gross Margin 32.2%; Reaffirms 2023 Guidance
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-39.04%
Tags
-
Rhea-AI Summary
Invitae announces enhanced chemistry of its Invitae Personalized Cancer Monitoring platform to detect circulating tumor DNA (ctDNA) as a biomarker for solid tumor malignancies. The assay features a patient-specific panel design with a sensitivity of >99% for detecting ctDNA at low variant allele frequencies. The company also received CLIA approval for the whole exome sequencing component of PCM as a stand-alone comprehensive genomic profiling assay.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
-
Rhea-AI Summary
Invitae (NYSE: NVTA) will report its Q3 2023 financial results on November 8, 2023. The conference call and webcast to discuss the results will be held at 4:30 p.m. Eastern / 1:30 p.m. Pacific. Participants can register for the conference call using the provided link. The webcast and slide deck will be available on the company's website. A replay of the webcast will also be archived on the website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.95%
Tags
Rhea-AI Summary
Invitae announces findings from the largest study on uncertain results from hereditary disease genetic testing. The study highlights the prevalence of variants of uncertain significance (VUS) and the need for detailed clinical information and family studies for proper interpretation. The study also found that the likelihood of identifying a VUS increased with larger gene panels and varied based on race, ethnicity, and ancestry. Over the course of the study, a large number of VUSs were reclassified, impacting more than 160,000 individuals. Invitae has invested in developing machine learning methods to reduce uncertainty in genetic testing results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.33%
Tags
-
Rhea-AI Summary
Invitae appoints David Sholehvar as Chief Operating Officer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
-
Rhea-AI Summary
Invitae announces results of collaborative study on universal hereditary cancer genetic testing in breast cancer patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
Rhea-AI Summary
Invitae showcases research at NSGC conference and presents Heart of Genetic Counseling Award
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.73%
Tags
Invitae Corporation
NYSE:NVTA
NVTA Rankings
NVTA Stock Data
5.59M
284.38M
1.51%
47.96%
23.65%
Medical Laboratories
Health Care and Social Assistance
US
San Francisco
About NVTA
invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people. specializing in genetic diagnostics for hereditary disorders, invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today. choose from our curated panels or design your own test for the same low price. today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. together we can improve healthcare for billions of people.